{"filing":{"accession_number":"0001193125-26-408224","cik":"0001400118","ticker":"SGMT","company_name":"Sagimet Biosciences Inc.","form":"8-K","filing_date":"2026-09-30","report_date":"2026-09-30","primary_document":"d96035d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1400118/000119312526408224/d96035d8k.htm"},"events":[{"id":35890,"run_id":33078,"accession_number":"0001193125-26-408224","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":false,"confidence":0.85,"summary":"Sagimet furnished an updated investor presentation under Regulation FD covering its clinical pipeline and business strategy, including denifanstat Phase 3 acne trial results, TVB-3567 development, and market opportunity.","company_name":"Sagimet Biosciences Inc.","ticker":"SGMT","filing_date":"2026-09-30","form":"8-K","submitted_at":null,"items":[{"id":40112,"accession_number":"0001193125-26-408224","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":false,"confidence":0.85,"reasoning":"This Item 7.01 disclosure involves an updated investor presentation on Sagimet's clinical pipeline and business strategy, furnished under Regulation FD. The presentation covers denifanstat's Phase 3 acne trial results, TVB-3567 development, and market opportunity—operational and strategic matters. The filing explicitly states the information is \"furnished\" and not \"filed,\" indicating it is a routine investor communication rather than a material event triggering mandatory disclosure. No material event (M\u0026A, executive change, financial restatement, covenant breach, etc.) is disclosed.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-30T10:11:41.288316+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":35891,"run_id":33078,"accession_number":"0001193125-26-408224","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.72,"summary":"Sagimet announced positive 52-week Phase 3 open-label extension trial results for denifanstat in acne, demonstrating proof-of-concept for its lead program, and terminated its at-the-market offering prospectus supplement.","company_name":"Sagimet Biosciences Inc.","ticker":"SGMT","filing_date":"2026-09-30","form":"8-K","submitted_at":null,"items":[{"id":40113,"accession_number":"0001193125-26-408224","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.72,"reasoning":"The Item 8.01 disclosure contains two distinct events: (1) announcement of positive 52-week Phase 3 open-label extension trial results for denifanstat in acne, and (2) termination of an at-the-market (ATM) offering prospectus supplement. The clinical trial results announcement represents a material operational/development milestone for a biotech company's lead program, demonstrating proof-of-concept and supporting advancement toward US Phase 3 trials. While the ATM termination is a capital-raising event, the primary focus and materiality of the disclosure centers on the clinical validation of denifanstat, which is operational in nature rather than fitting a specific financial category like debt_issuance or dilutive_issuance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-30T10:11:41.288316+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":40112,"accession_number":"0001193125-26-408224","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":false,"confidence":0.85,"reasoning":"This Item 7.01 disclosure involves an updated investor presentation on Sagimet's clinical pipeline and business strategy, furnished under Regulation FD. The presentation covers denifanstat's Phase 3 acne trial results, TVB-3567 development, and market opportunity—operational and strategic matters. The filing explicitly states the information is \"furnished\" and not \"filed,\" indicating it is a routine investor communication rather than a material event triggering mandatory disclosure. No material event (M\u0026A, executive change, financial restatement, covenant breach, etc.) is disclosed.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-30T10:11:41.288316+00:00","company_name":"Sagimet Biosciences Inc.","ticker":"SGMT","filing_date":"2026-09-30"},{"id":40113,"accession_number":"0001193125-26-408224","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.72,"reasoning":"The Item 8.01 disclosure contains two distinct events: (1) announcement of positive 52-week Phase 3 open-label extension trial results for denifanstat in acne, and (2) termination of an at-the-market (ATM) offering prospectus supplement. The clinical trial results announcement represents a material operational/development milestone for a biotech company's lead program, demonstrating proof-of-concept and supporting advancement toward US Phase 3 trials. While the ATM termination is a capital-raising event, the primary focus and materiality of the disclosure centers on the clinical validation of denifanstat, which is operational in nature rather than fitting a specific financial category like debt_issuance or dilutive_issuance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-30T10:11:41.288316+00:00","company_name":"Sagimet Biosciences Inc.","ticker":"SGMT","filing_date":"2026-09-30"}]}